Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma

被引：5
|
作者：
Shi, Yang [1 ,2 ]
Xiang, Zheng [4 ]
Yang, Huiyu [1 ,2 ]
Khan, Suliman [5 ]
Li, Ruizhe [3 ]
Zhou, Siran [1 ,2 ]
Ullah, Saif [1 ,2 ]
Zhang, Jiyu [1 ,2 ]
Liu, Bingrong [1 ,2 ]
机构：
[1] Zhengzhou Univ, Dept Gastroenterol, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China
[2] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450052, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Pathol, Zhengzhou 450052, Peoples R China
[4] Zhengzhou Univ, Henan Univ, Henan Prov Peoples Hosp, Dept Pathol,Peoples Hosp, Zhengzhou 450003, Peoples R China
[5] Zhengzhou Univ, Affiliated Hosp 2, Dept Cerebrovasc Dis, Zhengzhou 450000, Peoples R China
来源：
AGING-US | 2021年 / 13卷 / 11期
基金：
中国国家自然科学基金;
关键词：
histone deacetylase inhibitors; LMK-235; esophageal squamous cell carcinoma; tensin-3; histone acetylation; SRC FAMILY KINASES; HDAC INHIBITORS; PROTEIN; EPIGENETICS; COMBINATION; EXPRESSION; PACKAGE;
D O I：
10.18632/aging.203091
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Histone acetylation which regulates about 2-10% of genes has been demonstrated to be involved in tumorigenesis of esophageal squamous cell carcinoma (ESCC). In this study, we investigated the treatment response of ESCC to selective histone deacetylase inhibitor (HDACi) LMK-235 and potential biomarker predicting the treatment sensitivity. We identified tensin-3 (TNS3) which was highly over-expressed in ESCC as one of the down-regulated genes in response to LMK-235 treatment. TNS3 was found positively correlated with the tumor malignancy and poor prognosis in the patients. Silencing TNS3 significantly inhibited ESCC cell proliferation both in vitro and in vivo, sensitizing the treatment response to LMK-235. Our findings provide an insight into understanding the oncogenic role of TNS3 in ESCC and its clinical application for HDAC targeted therapy of ESCC.
引用
收藏
页码：15336 / 15352
页数：17
相关论文
共 50 条
  • [1] Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma
    Zhong, Lei
    Zhou, Shu
    Tong, Rongsheng
    Shi, Jianyou
    Bai, Lan
    Zhu, Yuxuan
    Duan, Xingmei
    Liu, Wenzhao
    Bao, Jinku
    Su, Lingyu
    Peng, Qian
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 616 - 624
  • [2] Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma
    Lei Zhong
    Shu Zhou
    Rongsheng Tong
    Jianyou Shi
    Lan Bai
    Yuxuan Zhu
    Xingmei Duan
    Wenzhao Liu
    Jinku Bao
    Lingyu Su
    Qian Peng
    Investigational New Drugs, 2019, 37 : 616 - 624
  • [3] Comment on "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma"
    Lin, Jiong
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1454 - 1455
  • [4] Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma”
    Jiong Lin
    Investigational New Drugs, 2021, 39 : 1454 - 1455
  • [5] Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma
    Toh, Y
    Yamamoto, M
    Endo, K
    Ikeda, Y
    Baba, H
    Kohnoe, S
    Yonemasu, H
    Hachitanda, Y
    Okamura, T
    Sugimachi, K
    ONCOLOGY REPORTS, 2003, 10 (02) : 333 - 338
  • [6] Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines
    Ma, Junfen
    Guo, Xiaobing
    Zhang, Shijie
    Liu, Hongchun
    Lu, Jing
    Dong, Ziming
    Liu, Kangdong
    Ming, Liang
    MOLECULAR MEDICINE REPORTS, 2015, 11 (06) : 4525 - 4531
  • [7] Histone deacetylase inhibitors in oral squamous cell carcinoma treatment
    Tasoulas, Jason
    Giaginis, Constantinos
    Patsouris, Efstratios
    Manolis, Evangelos
    Theocharis, Stamatios
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (01) : 69 - 78
  • [8] Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo
    Ma, Junfen
    Li, Nan
    Zhao, Jimin
    Lu, Jing
    Ma, Yanqiu
    Zhu, Qinghua
    Dong, Ziming
    Liu, Kangdong
    Ming, Liang
    ONCOLOGY LETTERS, 2017, 13 (06) : 4868 - 4874
  • [9] Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines
    Enzenhofer, Elisabeth
    Kadletz, Lorenz
    Stanisz, Isabella
    Kotowski, Ulana
    Seemann, Rudolf
    Schmid, Rainer
    Thurnher, Dietmar
    Heiduschka, Gregor
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (05): : 900 - 907
  • [10] The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma
    Wu, Ning
    Zhu, Yingfeng
    Xu, Xiao
    Zhu, Yongjun
    Song, Yang
    Pang, Liewen
    Chen, Zhiming
    JOURNAL OF CANCER, 2018, 9 (06): : 987 - 997
12345